Levmetamfetamine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Levmetamfetamine: From a Marketed Vapor Inhaler to Nasal Cavity Disease
One-Sentence Summary
Levmetamfetamine is marketed in the US as an inhalant in “Vapor Inhaler” products, but the record lists no approved indication text. The TxGNN model predicts it may be effective for nasal cavity disease, but there are currently 0 clinical trials and 0 publications behind this prediction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available, and the record lists no original indication for levmetamfetamine. No mechanism can be verified from the supplied data.
Background knowledge, which the supplied data does not support, suggests levmetamfetamine is a sympathomimetic (adrenergic) agent used in over-the-counter inhaled nasal decongestants. If so, the very high score (99.88%) may reflect an existing labeled use rather than a genuine repurposing signal. This should be checked against the drug label and DrugBank before any further use.
The second-ranked prediction, acute laryngopharyngitis (score 99.85%), has no supporting trials or publications either. A vasoconstrictive or decongestant effect on upper-airway mucosa is plausible in principle but speculative. It is most likely a network-proximity effect from the nasal indication, and it does not establish efficacy for laryngopharyngeal inflammation or infection.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The record shows 7 authorizations in total. The 5 below are the ones listed. All share license number M012, and none has an approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| M012 | Vapor Inhaler | Inhalant | Topco Associates LLC |
| M012 | Vapor Inhaler | Inhalant | Dolgencorp Inc. |
| M012 | Vapor Inhaler | Inhalant | Valu Merchandisers Company |
| M012 | Vapor Inhaler | Inhalant | Supervalu Inc. |
| M012 | Vapor Inhaler | Inhalant | Walgreens |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is a model prediction only (L5), with no clinical trials or literature. The high score for nasal cavity disease may simply reflect an existing labeled use rather than a new one, and this cannot be confirmed from the current data.
To proceed, the following is needed:
- Check the current US label and DrugBank record to confirm the approved indication and whether nasal cavity disease is already a labeled use
- Mechanism of action data (MOA)
- Package insert warnings and contraindications for safety screening
- Any clinical or preclinical evidence for acute laryngopharyngitis before pursuing it as a separate indication
These results are for research reference only and do not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.